Spots Global Cancer Trial Database for Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Official Title: A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Study ID: NCT02219178
Conditions
Study Description
Brief Summary: This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Waterford, Waterford, Co Waterford, Ireland
Cork University Hospital, Cork, , Ireland
Beaumont Hospital, Dublin, , Ireland
Mater Misericordiae University Hospital, Dublin, , Ireland
St James's Hospital, Dublin, , Ireland
University Hospital Galway, Galway, , Ireland
University Hospital Limerick, Limerick, , Ireland
Midlands Regional Hospital, Tullamore, , Ireland
Contact Details
Name: Peter O'Gorman, Dr
Affiliation: Mater Misericordiae University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
